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Osteoporosis is a disease that increases skeletal fracture
risk and places a significant health and economic
burden on patients, families, and health systems. Many
treatment options exist, but patient use is suboptimal,
thus undermining the potential cost-effectiveness of
treatments. In the previous issue of Arthritis Research &
Therapy, Hiligsmann and colleagues expanded the
findings of previous studies to report, from a sample of
257 patients with osteoporosis, the preference to trade
off clinical outcomes for the amenity provided by
convenient dosing regimens. This editorial critiques the
strengths and limitations of the methods, discusses the
potential utility of patient treatment preferences, and
suggests avenues for further research.hypothetical treatments. An underlying assumption is thatIn the previous issue of Arthritis Research & Therapy,
Hiligsmann and colleagues explored the treatment prefer-
ences of patients with, or at risk of, osteoporosis [1].
Osteoporosis is a disease characterized by impaired bone
quality, leading to increased fracture risk at multiple
skeletal sites and significant morbidity and mortality [2].
The health and economic burden of osteoporosis to
individuals, families, and health systems is substantial, and
osteoporotic fractures represent 0.83% of the global
burden of non-communicable diseases [3]. Currently, the
prevalence of osteoporosis is higher in females, although
men have higher fracture-related mortality rates [4]. The
prevalence of osteoporosis and incidence of osteoporotic
fractures are expected to increase, particularly as the
population ages.Correspondence: tlaba@georgeinstitute.org.au
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use of cost-effective drug treatment, is critical to sustainable
health budgets worldwide. Several cost-effective treatment
options are known to exist, offering patients a variety of
dosing frequencies (for example, weekly and annually) and
routes (for example, oral and intravenous). However,
patients may for various reasons fail to take up or persist
with osteoporotic treatments [5]. Understanding patient
preferences for treatments can help clinicians prescribe
treatments that patients like (and presumably will take) and
can assist health-care funders identify treatments that are
more likely to be cost-effective in practice.
In the study by Hiligsmann and colleagues [1], Discrete
Choice Experiment (DCE) was used to elicit treatment
preferences. DCE is a robust survey methodology that
presents respondents with successive choices between
choice is driven by trading between treatment attributes
(for example, side effects and efficacy). When econometric
modeling is used, the relative importance of attributes and
the extent to which respondents trade between attributes of
treatment decisions can be quantified [6]. DCE is used
widely in health to address problems ranging from asses-
sing medication adherence [7,8] to predicting the uptake of
government health policies [9].
The capacity of a DCE to accurately understand behavior
is dependent on the choice of attributes posed to respon-
dents. The attributes used by Hiligsmann and colleagues
[1] include efficacy (that is, reduction of fracture risk), side
effects, administration mode and frequency, and patient
costs. Importantly, these attributes were determined though
the analysis of qualitative data collected from patients with
osteoporosis [10]. Furthermore, a ‘no treatment’ option was
posed, thereby mimicking real-life choices. These methodo-
logical features strengthen the research findings.
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treatment preferences, the findings that patients prefer
treatments offering higher efficacy, lower costs, and less
frequent dosing regimens and that not all patients have the
same preferences are not surprising. This study does, how-
ever, evaluate additional administration routes currently or
soon to be available, the side effects deemed important by
patients, and the perspectives of men - currently under-
represented in the literature yet predicted to contribute
significantly to the total cost burden of osteoporosis [4].
Furthermore, the extent of efficacy and personal monetary
cost that participants were willing to forego in exchange for
desired dosing characteristics were quantified. For decision-
makers, this evidence demonstrates that maximizing treat-
ment efficacy and safety is not unequivocally important to
all patients, particularly if at the cost of less convenient
administration attributes.
There are some caveats to these findings and thus room
for further research. First, all DCEs are subject to hypothet-
ical bias: what respondents say they would do may differ
from what they actually do, especially when experiencing
the consequence of a choice. Hypothetical bias is unavoid-
able in DCEs but can be minimized. Combining results
with actual choice data (for example, real-world data
capturing actual choices by patients) is one technique that
needs further exploration in health.
Second, preferences were captured from consecutive
patients attending one osteoporosis center and at one point
in time. In addition to investigating the external validity of
the findings, the temporal variations in preferences need to
be better understood, particularly as patient preferences are
likely to change over the course of treatment.
Finally, further work is needed to understand prefer-
ences in subgroups. For instance, the results comparing
preferences of high- versus low-risk patients suggest that
patients at high risk have an increased preference for
medication with lower efficacy compared with low-risk
patients; this is somewhat counterintuitive and needs
further investigation. Research into the preferences of
men and racial and ethnic minorities is needed given the
rapidly increasing share of the osteoporosis disease burden
projected in such populations [4].
In summary, Hiligsmann and colleagues have provided
further evidence of the treatment preferences of patients
with osteoporosis, highlighting the willingness of patients
to trade off clinical outcomes for the amenity provided by
convenient dosing regimens. The authors have good
reasons to believe that this information will be of interest
to clinicians and health-care decision-makers. However,
given the suboptimal use of osteoporotic medications by
patients, more work is needed to further understand
how stated treatment preferences translate to real-world
patient use of medications over time. Ultimately, this will
better inform the interpretation of cost-effectivenessevidence for osteoporosis treatments and promote more
effective and cost-effective treatment of this condition.
Abbreviation
DCE: Discrete Choice Experiment.
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